Categories on this page


Savings

✦ YOU MAY PAY AS LITTLE AS

Pay as little as $0 per month with the Inluriyo® (imlunestrant) Savings Card, if eligible and commercially insured with coverage for Inluriyo.

Governmental beneficiaries excluded, terms and conditions apply.

$0

per month*

If eligible & commercially insured with coverage

*Month is defined as 28 days.

Inluriyo Savings Card Terms and Conditions


By enrolling in and using the Inluriyo Savings Card Program (“Program”) and using the Inluriyo Savings Card (“Card”), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:

Card Eligibility:

  1. You have been prescribed Inluriyo® (imlunestrant) for an approved use consistent with FDA approved product labeling;
  2. You are enrolled in a commercial drug insurance plan and have coverage for Inluriyo;
  3. You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program;
  4. You are a resident of the United States or Puerto Rico; and
  5. You are 18 years of age or older.

Card Terms and Conditions

For patients with commercial drug insurance coverage for Inluriyo: You must have commercial drug insurance that covers Inluriyo and a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $0 for a 1-month prescription fill of Inluriyo. Month is defined as 28 days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and separate maximum annual savings of up to $10,600 per calendar year. Card may be used for a maximum of up to 14 prescription fills per calendar year. Participation in the Program requires a valid patient HIPAA authorization upon enrollment into the Program. Except where prohibited by applicable state law, Card monthly and annual savings are reduced if Lilly identifies that you are enrolled in a plan or program, sometimes called a maximizer plan, that adjusts your cost sharing amount to be equal to or include some portion of the savings provided by the Card and attempts to prevent the savings from this Card from being applied to your out-of-pocket costs, including but not limited to copayments, coinsurances, and deductibles (“Maximizer”). If the Program identifies you are enrolled in a Maximizer, Card savings are reduced to a maximum monthly savings of up to $25 and a separate maximum annual savings of up to $350 per calendar year. If you have reason to believe that the Program erroneously identified enrollment in a Maximizer, please call the Inluriyo Savings Card Program at 1-844-583-3550. Subject to Lilly USA, LLC's (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

Additional Program Terms and Conditions

If you have an insurance plan that is participating in an alternate funding program (“AFP”) that requires you to apply to the Inluriyo Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Inluriyo, you are not eligible for and are prohibited from using the Inluriyo Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member's use of Inluriyo Savings Card Program. You agree to inform the Inluriyo Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Inluriyo, only allows partial coverage for Inluriyo, removes coverage for Inluriyo and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Inluriyo, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Inluriyo. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Inluriyo Savings Card and agree to call the Inluriyo Savings Card Program at 1-844-583-3550 to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Inluriyo. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are non-transferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly's sole discretion to terminate, rescind, revoke, or amend Card eligibility and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card's eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Inluriyo Savings Card Program may change from time to time; the most current version can be found at https://www.inluriyo.lilly.com/savings-support#terms-and-conditions. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly's right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

Support

Lilly Support Services™ for Inluriyo

Ongoing Support

Through 1-on-1 check-ins, your Lilly Support Services for Inluriyo team can support you by:

pill icon

Helping to get you started on Inluriyo quickly

phone call icon

Being there to answer specific questions or just lend an ear during a live call

message icon

Connecting you with relevant resources and information over emails and/or texts

Ask your doctor or care team about enrolling in these services


Interim Access

Interim Access Program for Inluriyo®

The Inluriyo Interim Access Program may provide a temporary supply of Inluriyo at no cost to insured, eligible patients who have been prescribed Inluriyo for the first time and are experiencing a delay in their insurance coverage decision. See terms and conditions below.† To be eligible, you must be: (1) prescribed Inluriyo for the first time, (2) experiencing a minimum 5-business-day delay in insurance coverage determination, (3) prescribed Inluriyo for an FDA-approved indication or an indication medically supported by CMS-recognized compendia, (4) enrolled in Lilly Support Services for Inluriyo, and (5) a resident of the US or Puerto Rico.

†TERMS AND CONDITIONS: The Inluriyo Interim Access Program (or “Program”) provides a 14-day supply of Inluriyo at no charge for eligible, insured patients who are: 1) prescribed Inluriyo for the first time, 2) experiencing a minimum 5-business-day delay in insurance coverage determination, 3) prescribed Inluriyo for an FDA-approved indication or an indication medically supported by CMS-recognized compendia, 4) enrolled in Lilly Support ServicesTM, and 5) residents of the United States or Puerto Rico. May not be combined with any other offer. Not available to patients whose insurers have made a final determination to deny the patient coverage for Inluriyo. If a denial is received after the initial 5 business days have passed and appeal rights are being pursued, or if there is a persistent coverage delay, the patient, under appropriate circumstances, may be eligible for up to 3 additional 14-day supplies of Inluriyo. Product provided through the Program is only available through the Program noncommercial specialty pharmacy. Product is provided free of charge and may not be sold, bartered, or returned for credit. Reimbursement cannot be sought from any third party for product provided under the Program. Patients enrolled in Medicare Part D are prohibited from counting any portion of the cost of the product provided under the Program toward true out-of-pocket (“TrOOP”) costs for prescription drug calculations. No purchase contingency or other obligation accompanies Program participation. This Program is not health insurance and does not guarantee coverage. Lilly reserves the right to change or end the Program at any time. Benefits under the Program are not transferable.

Lilly Support Services logo.

Questions about Inluriyo?

Call Lilly Support Services™ at 1-800-LillyRx (1-800-545-5979) from Monday to Friday.

There are multiple ways to fill your prescriptions.

Your initial medications may come from your doctor or another member of your healthcare team. You may continue to fill your prescriptions through your healthcare provider or through specialty pharmacies.

If you are prescribed two Lilly medications, they may come from two different specialty pharmacies.

Here's how a specialty pharmacy works with you to fill your prescription:

prescription icon

Your doctor will send your prescription to a specialty pharmacy (or multiple specialty pharmacies)

payment icon

The specialty pharmacy can check if your prescription is covered by your insurance plan and can also help assess your eligibility for the Savings Card(s)

calendar icon

The specialty pharmacy will contact you to schedule a date and time to deliver your medication

Governmental beneficiaries excluded, terms and conditions apply.

Lilly Support Services logo.

Questions about Inluriyo?

Call Lilly Support Services™ at 1-800-LillyRx (1-800-545-5979) from Monday to Friday.

Learn more about Lilly Support Services for Verzenio.

Helpful Resources


Get tools, insights, and guidance that may help throughout your Inluriyo journey.

Inluriyo + Verzenio Patient Experience Brochure

Download the Patient Experience Brochure for helpful information about starting and staying on Inluriyo.

Inluriyo Patient Experience Brochure

Download the Patient Experience Brochure for helpful information about starting and staying on Inluriyo alone.

Support groups

Breast cancer support groups—connect with others who understand your diagnosis.

There are many organizations that provide opportunities to connect in person or online for support. We've put together a list of support groups that can help you connect with other women who have breast cancer and share your experiences.

This information has been provided by the listed organizations, and Lilly is not responsible for the content. Its use on this site is not intended to serve as an endorsement of the listed organization.

All third-party organization names and other trademarks are the property of their respective trademark owners. These trademark owners are not affiliated with Lilly and they do not sponsor or endorse these materials.

Logo for BreastCancer.org

BreastCancer.org was founded over 25 years ago and has become the leading digital resource for people facing the complex challenges of breast cancer diagnosis, treatment, and survivorship. Breastcancer.org uniquely uses excellence in program development and implementation to focus on helping people deal with the here-and-now questions and challenges they face by providing actionable, medically vetted information combined with a supportive digital peer community. It is critical that people have trustworthy information and guidance when considering life-changing choices about treatment and care, especially when urgent decisions need to be made. The education and support resources on Breastcancer.org — available at no cost in English and Spanish — serve an enormous purpose for people who count on access to reliable, relevant, easy-to-understand, and actionable guidance.

Logo for Living Beyond Breast Cancer (LBBC)

Living Beyond Breast Cancer (LBBC) is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical and evidence-based content. 30 years since its inception, the organization remains committed to creating a culture of acceptance—where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope.

Logo for Sister's Network.

Sister's Network® Inc. (SNI), founded in 1994, is a national black breast cancer survivorship organization that provides breast cancer awareness education, patient advocacy, support, and financial assistance for survivors nationwide. SNI has over 25 survivor-run affiliate chapters located in major U.S. cities.

Logo for Susan G. Komen.

Susan G. Komen has a mission to save lives by meeting the most critical needs of the community and investing in breakthrough research to prevent and cure breast cancer. Their helpline provides emotional support, guidance, and information on breast health, breast cancer, local and national resources, as well as clinical trials. Additionally, Susan G. Komen offers support through Facebook groups, financial assistance, and resources to help you access the most up-to-date information on breast cancer risk factors, screening, diagnosis, treatment, metastatic breast cancer, survivorship, and more.

Logo for Unite for HER.

Unite for HER (Helping to Empower and Restore) is a national nonprofit organization that supports those affected by breast and ovarian cancers. Its vision is that every person with breast and ovarian cancers will feel the support of a loving community, and will have access to comprehensive education, services, and tools that enrich their health and well-being. Unite for HER's comprehensive Wellness Programs provide members with free access to education, support, and integrative therapies and services like nutrition, yoga, Reiki, and more.

Logo for Young Survival Coalition (YSC).

Young Survival Coalition (YSC) serves young adults diagnosed with breast cancer age 40 and under by providing tailored education, support and community programs to them and their caregivers.

phone icon

Lilly Support Services

1-800-LillyRx

(1-800-545-5979)

Monday – Friday, 8 am – 10 pm ET

question icon

Savings Card Support

1-844-583-3550

For Savings Card-specific questions and troubleshooting

Lilly Support Services™ is not made up of medical professionals. Your doctor is your source for medical advice. Inluriyo support programs and offerings are not a guarantee of coverage. Terms and conditions apply for all programs. See the Inluriyo enrollment form for details.

Lilly Support Services™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

CMAT-30956 09/2026

INDICATIONS AND SAFETY SUMMARIES
This document contains Consumer Brief Summary information for Inluriyo® (imlunestrant) and Verzenio® (abemaciclib). Review both sections below for complete information on each product.

Inluriyo® (imlunestrant)

Indication and Safety Summary

Inluriyo (en-loo-ree-yoh) is a prescription medicine that is used alone or in combination with the medicine abemaciclib (Verzenio) to treat adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after at least 1 line of endocrine therapy.

Your healthcare provider will perform a test to make sure Inluriyo is right for you.

When Inluriyo is used in combination with abemaciclib, read the Patient Information for abemaciclib (Verzenio).

It is not known if Inluriyo is safe and effective in children.

Before taking Inluriyo, tell your healthcare provider about all your medical conditions, including if you:

  • Have liver problems.
  • Are pregnant or plan to become pregnant. Inluriyo can harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if Inluriyo passes into breastmilk. Do not breastfeed during treatment with Inluriyo and for 1 week after the last dose. Your healthcare provider will tell you how long you should not breastfeed after combination treatment with Inluriyo and abemaciclib.

Females who are able to become pregnant:

  • Your healthcare provider will do a pregnancy test before you start treatment with Inluriyo.
  • Use effective birth control (contraception) during treatment with Inluriyo and for 1 week after the last dose.
  • Your healthcare provider will tell you how long you should use birth control (contraception) after combination treatment with Inluriyo and abemaciclib.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Inluriyo.

Males with female partners who are able to become pregnant:

  • Use effective birth control (contraception) during treatment with Inluriyo and for 1 week after the last dose.

Most common side effects of Inluriyo when taken alone include decreased hemoglobin (anemia), muscle and joint pain, decreased white blood cell counts, increased liver function tests, decreased calcium blood levels, tiredness, diarrhea, increased triglyceride and cholesterol blood levels, nausea, decreased platelet counts, constipation, and stomach-area (abdominal) pain. These are not all the possible side effects of Inluriyo.

Most common side effects of Inluriyo when taken with abemaciclib include decreased white blood cell counts, diarrhea, decreased hemoglobin (anemia), nausea, decreased platelet counts, tiredness, increased triglycerides and cholesterol blood levels, infections, increased liver function tests, increased creatinine blood levels, vomiting, muscle and joint pain, stomach-area (abdominal) pain, decreased appetite, rash, cough, headache, and weight loss. These are not all the possible side effects of Inluriyo in combination with abemaciclib.

Your healthcare provider will check your blood levels, including monitoring your triglyceride and cholesterol blood levels, before and during treatment with Inluriyo.

Your healthcare provider may change your dose, temporarily stop, or completely stop treatment with Inluriyo if you develop certain side effects.

Inluriyo may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Inluriyo and other medicines may affect each other, causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How to take Inluriyo

  • Take Inluriyo exactly as your healthcare provider tells you.
  • Your healthcare provider may change or stop your dose if needed. Do not stop taking Inluriyo or change the dose unless instructed to do so by your healthcare provider.
  • Take Inluriyo once daily, at approximately the same time each day.
  • Take on an empty stomach, at least 2 hours before food or 1 hour after food.
    • Swallow Inluriyo tablets whole. Do not chew, crush, or split the tablets.
  • If you miss a dose by 6 hours or more or vomit after taking Inluriyo, do not take another dose on that day. Take your next dose the following day at your regularly scheduled time.

Learn more

Inluriyo is a prescription medicine available as 200 mg tablets. For more information, call 1-800-545-5979 [or go to www.inluriyo.lilly.com].

This summary provides basic information about Inluriyo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Inluriyo and how to take it. Your healthcare provider is the best person to help you decide if Inluriyo is right for you.

VERZENIO® (abemaciclib)

Indication and Safety Summary

Verzenio (ver-ZEN-ee-oh) is a prescription medicine used in adults:

  • In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer with a high risk of coming back as determined by your healthcare provider.
  • In combination with an aromatase inhibitor as the first endocrine-based therapy to treat HR-positive, HER2-negative breast cancer that is advanced or has spread to other parts of the body (metastatic).
  • In combination with fulvestrant to treat HR-positive, HER2-negative breast cancer that is advanced or has spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy.
  • In combination with imlunestrant (Inluriyo) to treat estrogen receptor (ER)-positive, HER2-negative, estrogen receptor-1 (ESR1)-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after at least 1 line of endocrine therapy. Your health care provider will perform a test to make sure Verzenio in combination with Imlunestrant is right for you.
  • Alone to treat HR-positive, HER2-negative metastatic breast cancer that is advanced or has spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy and prior chemotherapy for metastatic disease.

When Verzenio is used in combination with fulvestrant, tamoxifen, imlunestrant, or an aromatase inhibitor, also read the Patient Information or Medication Guide for the prescribed product if available. Ask your healthcare provider if you are not sure.

It is not known if Verzenio is safe and effective in children.

Warnings - Verzenio may cause serious side effects, including:

Diarrhea is common with Verzenio, may sometimes be severe, and may lead to a loss of large amounts of fluid and salt causing dehydration. The most common time to develop diarrhea is during the first month of Verzenio treatment.

If you have any loose stools, start taking an antidiarrheal medicine (such as loperamide), drink more fluids, and tell your healthcare provider right away.

Low white blood cell counts (neutropenia) are common with Verzenio and may cause serious infections that can lead to death. Your healthcare provider should check your white blood cell counts before and during treatment. Tell your healthcare provider right away if you develop signs and symptoms of an infection, such as fever and chills.

Verzenio may cause severe or life-threatening inflammation of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you develop any new or worsening signs or symptoms, including trouble breathing or shortness of breath, cough with or without mucus, or chest pain.

Verzenio can cause serious liver problems. Your healthcare provider should do blood tests to check your liver before and during treatment. Tell your healthcare provider right away if you develop any of the following signs or symptoms of liver problems including feeling very tired, pain on the upper right side of your stomach area (abdomen), loss of appetite, or bleeding or bruising more easily than normal.

Verzenio may cause blood clots in your veins, or in the arteries of your lungs. Verzenio may cause serious blood clots that have led to death. Tell your healthcare provider right away if you develop signs and symptoms of a blood clot including pain or swelling in your arms or legs, shortness of breath, chest pain, rapid breathing, or rapid heart rate.

If you develop serious side effects during treatment with Verzenio, your healthcare provider may reduce your dose, temporarily stop, or completely stop treatment with Verzenio.

Most common side effects of Verzenio include diarrhea, infections, low white blood cell counts (neutropenia and leukopenia), tiredness (fatigue), stomach area (abdominal) pain, nausea, low red blood cell counts (anemia), and vomiting. These are not all the possible side effects of Verzenio.

Verzenio may cause fertility problems in males that may affect your ability to father a child.

Tell your healthcare provider if you have any side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before you use Verzenio

Tell your healthcare provider about all your medical conditions, including if you:

  • Have fever, chills, or any other signs of infection.
  • Have a history of blood clots in your veins.
  • Have lung or breathing problems.
  • Have liver or kidney problems.
  • Are pregnant, plan to become pregnant, or are breastfeeding. Verzenio can harm your unborn baby.
    • Your healthcare provider will do a pregnancy test before you start treatment with Verzenio.
    • Use effective birth control (contraception) during treatment with Verzenio and for 3 weeks after the last dose of Verzenio.
    • Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Verzenio.
  • About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Verzenio may affect the way other medicines work, and other medicines may affect how Verzenio works, causing serious side effects. Especially tell your healthcare provider if you take a medicine that contains ketoconazole. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How to take Verzenio

  • Take Verzenio exactly as your healthcare provider tells you.
  • Your healthcare provider may change your dose if needed. Do not stop taking Verzenio or change the dose without talking to your healthcare provider.
  • Verzenio may be taken with or without food.
  • Swallow Verzenio tablets whole. Do not chew, crush, or split the tablets before swallowing. Do not take Verzenio tablets if they are broken, cracked, or damaged.
  • Take your doses of Verzenio at about the same time every day.
  • If you miss a dose of Verzenio, skip the missed dose and take your next dose at your regularly scheduled time.
  • If you vomit after taking a dose of Verzenio, do not take another dose. Take your next dose at your regularly scheduled time.

What to avoid during treatment

  • Avoid taking ketoconazole during treatment with Verzenio. Tell your healthcare provider if you take a medicine that contains ketoconazole.
  • Avoid grapefruit and products that contain grapefruit during treatment with Verzenio. Grapefruit may increase the amount of Verzenio in your blood.

Learn more

Verzenio is a prescription medicine available as 50, 100, 150, and 200 mg tablets. For more information, call 1-800-545-5979 [or go to www.verzenio.lilly.com].

This summary provides basic information about Verzenio but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your healthcare provider about Verzenio and how to take it. Your healthcare provider is the best person to help you decide if Verzenio is right for you.

IN VZ CON BS COMBO APP

Inluriyo® and Verzenio® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.